MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

Phase 3
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2001-01-01
Last Posted Date
2011-06-16
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
1587
Registration Number
NCT00007683
Locations
🇬🇧

Scunthorpe General Hospital, Scunthorpe, North Lincolnshire, United Kingdom

🇨🇦

Alder Medical Centre, Campbell River, British Columbia, Canada

🇺🇸

Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock, No. Little Rock, Arkansas, United States

and more 131 locations

Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis

Completed
Conditions
Venous Thrombosis
Cardiovascular Diseases
Venous Thromboembolism
First Posted Date
2000-05-26
Last Posted Date
2016-05-13
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00005684

Aspirin Or Warfarin To Prevent Stroke

Phase 3
Terminated
Conditions
Atherosclerosis
Constriction, Pathologic
Stroke
Cerebral Infarction
First Posted Date
2000-02-28
Last Posted Date
2006-06-06
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Registration Number
NCT00004728
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Treatment for Blood Clots in the Veins of the Legs

Phase 1
Completed
Conditions
Embolism
Thrombophlebitis
First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
20
Registration Number
NCT00001713
Locations
🇺🇸

National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States

Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)

Phase 3
Completed
Conditions
Arrhythmia
Cardiovascular Diseases
Atrial Fibrillation
Heart Diseases
Thrombophlebitis
Cerebrovascular Accident
Cerebral Embolism and Thrombosis
Cerebrovascular Disorders
First Posted Date
1999-10-28
Last Posted Date
2014-04-10
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT00000517

Post Coronary Artery Bypass Graft (CABG) Study

Phase 3
Completed
Conditions
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Myocardial Ischemia
First Posted Date
1999-10-28
Last Posted Date
2016-04-14
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000463

Prevention of Recurrent Venous Thromboembolism (PREVENT)

Phase 3
Completed
Conditions
Cardiovascular Diseases
Peripheral Vascular Diseases
Heart Diseases
Thromboembolism
Vascular Diseases
Venous Thromboembolism
First Posted Date
1999-10-28
Last Posted Date
2016-03-16
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000614

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Phase 3
Completed
Conditions
Heart Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Diabetes Mellitus
First Posted Date
1999-10-28
Last Posted Date
2016-07-12
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000539
© Copyright 2025. All Rights Reserved by MedPath